Carrageenan-Based Gel Retains Limited Anti-HIV-1 Activity 8–24 Hours After Vaginal Application by HIV-Infected Thai Women Enrolled in a Phase I Safety Trial
Advanced Search
Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.
 
 
i

Superseded

This Document Has Been Replaced By:

i

Retired

This Document Has Been Retired

i

Up-to-date Information

This is the latest update:

Carrageenan-Based Gel Retains Limited Anti-HIV-1 Activity 8–24 Hours After Vaginal Application by HIV-Infected Thai Women Enrolled in a Phase I Safety Trial
Filetype[PDF-77.47 KB]


No Related Documents.

You May Also Like:

  1. Filetype[PDF - 191.37 KB]
    Personal Author:
    Kashuba, Angela DM; Gengiah, Tanuja N; Werner, Lise; Yang, Kuo-Hsiung; White, Nicole R; Karim, Quarraisha Abdool; Abdool Karim, Salim S.;
    Published Date:
    Jul 1 2015
    Source:
    J Acquir Immune Defic Syndr. 69(3):264-269.
    Description:
    ObjectiveThe CAPRISA 004 trial showed that coitally-dosed tenofovir 1% gel reduced HIV acquisition by 39% overall and 54% when used consistently. The objective of this analysis was to ascertain its pharmacokinetic-pharmacodynamic relationship to prot...
    File Type:
    Filetype[PDF - 191.37 KB]
  2. Filetype[PDF - 332.24 KB]
    Personal Author:
    Kaleebu, Pontiano; Kirungi, Wilford; Watera, Christine; Asio, Juliet; Lyagoba, Fred; Lutalo, Tom; Kapaata, Anne A.; Nanyonga, Faith; Parry, Chris M.; Magambo, Brian; Nazziwa, Jamirah; Nannyonjo, Maria; Hughes, Peter; Hladik, Wolfgang; Ruberantwari, Anthony; Namuwenge, Norah; Musinguzi, Joshua; Downing, Robert; Katongole-Mbidde, Edward;
    Corporate Authors:
    The HIV Drug Resistance Working group
    Published Date:
    Dec 23 2015
    Source:
    PLoS One. 10(12).
    Series:
    PEPFAR
    Description:
    BackgroundWith the scale-up of antiretroviral therapy (ART), monitoring programme performance is needed to maximize ART efficacy and limit HIV drug resistance (HIVDR).MethodsWe implemented a WHO HIVDR prospective survey protocol at three treatment ce...
    File Type:
    Filetype[PDF - 332.24 KB]
  3. Filetype[PDF - 475.39 KB]
    Personal Author:
    Chohan, Bhavna H.; Tapia, Kenneth; Merkel, Michele; Kariuki, Arphaxad C; Khasimwa, Brian; Olago, Agatha; Gichohi, Richard; Obimbo, Elizabeth M; Wamalwa, Dalton C;
    Published Date:
    Jul 01 2013
    Source:
    J Acquir Immune Defic Syndr. 63(3):e87-e93
    Description:
    BackgroundPooled viral load (VL) testing with two different testing strategies was evaluated as a potential cost-saving method to monitor antiretroviral therapy (ART) in HIV-infected children receiving ART in a resource-limited setting.MethodsArchive...
    File Type:
    Filetype[PDF - 475.39 KB]
  4. Filetype[PDF - 744.97 KB]
    Personal Author:
    Chung, Michael H.; McGrath, Christine J.; Beck, Ingrid A.; Levine, Molly; Milne, Ross S.; So, Isaac; Andersen, Nina; Dross, Sandra; Coombs, Robert W.; Chohan, Bhavna; Yatich, Nelly; Kiptinness, Catherine; Sakr, Samah R.; Kiarie, James N.; Frenkel, Lisa M.;
    Published Date:
    December 07 2019
    Source:
    Lancet HIV.
    Description:
    BackgroundAlthough experts have recommended testing for pretreatment drug resistance (PDR) prior to ART initiation, there is little evidence to support its implementation. Our aim was to determine whether an inexpensive point mutation assay can impro...
    File Type:
    Filetype[PDF - 744.97 KB]
  5. Filetype[PDF - 1.00 MB]
    Personal Author:
    DONNELL, Deborah; RAMOS, Eric; CELUM, Connie; BAETEN, Jared; DRAGAVON, Joan; TAPPERO, Jordan; LINGAPPA, Jairam R.; RONALD, Allan; FIFE, Kenneth; COOMBS, Robert W;
    Published Date:
    Sep 10 2017
    Source:
    AIDS. 31(14):2007-2016.
    Description:
    ObjectiveTo investigate whether oral pre-exposure prophylaxis (PrEP) alters timing and patterns of seroconversion when PrEP use continues after HIV-1 infection.DesignRetrospective testing of the timing of Fiebig stage HIV-1 seroconversion in the Part...
    File Type:
    Filetype[PDF - 1.00 MB]